Global Partners LP (GLP) Income Statement Analysis

See more : Algernon Pharmaceuticals Inc. (AGN.CN) Income Statement Analysis – Financial Results

Complete financial analysis of Global Partners LP (GLP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Global Partners LP, a leading company in the Oil & Gas Midstream industry within the Energy sector.

You may be interested

Global Partners LP (GLP)

Industry: Oil & Gas Midstream

Sector: Energy

Website: https://www.globalp.com

About Global Partners LP

Global Partners LP engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, and propane to wholesalers, retailers, and commercial customers in the New England states, Mid-Atlantic region, and New York. The company is also involved in the transportation of petroleum products and renewable fuels through rail from the mid-continent region of the United States and Canada. Its Wholesale segment sells home heating oil, branded and unbranded gasoline and gasoline blendstocks, diesel, kerosene, residual oil, and propane to home heating oil retailers and wholesale distributors. It also aggregates crude oil through truck or pipeline in the mid-continent region of the United States and Canada, as well as transports it through rail and ships it through barge to refiners. The company's Gasoline Distribution and Station Operations segment sells branded and unbranded gasoline to gasoline station operators and sub-jobbers; operates gasoline stations and convenience stores; and provides car wash, lottery, and ATM services, as well as leases gasoline stations. Its Commercial segment sells and delivers unbranded gasoline, home heating oil, diesel, kerosene, residual oil, and bunker fuel to customers in the public sector, as well as to commercial and industrial end-users; and sells custom blended fuels. As of December 31, 2021, the company had a portfolio of 1,595 owned, leased, and supplied gasoline stations, which included 295 directly operated convenience stores; and owned, leased, or maintained storage facilities at 26 bulk terminals with a collective storage capacity of 11.9 million barrels. Global GP LLC serves as the general partner of the company. The company was incorporated in 2005 and is based in Waltham, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Revenue	16.49B	18.88B	13.25B	8.32B	13.08B	12.67B	8.92B	8.24B	10.31B	17.27B	19.59B	17.63B	14.84B	7.80B	5.82B	9.02B	6.76B	4.47B	1.25B	3.19B	2.48B	1.59B	1.75B
Cost of Revenue	15.98B	17.78B	12.53B	7.60B	12.42B	12.02B	8.34B	7.69B	9.72B	16.73B	19.18B	17.29B	14.63B	7.63B	5.67B	8.90B	6.63B	4.36B	1.22B	3.11B	2.41B	1.54B	1.69B
Gross Profit	513.83M	1.10B	719.26M	721.14M	662.76M	650.41M	583.05M	546.49M	597.67M	542.61M	405.83M	333.49M	209.60M	166.72M	149.83M	119.79M	126.98M	113.23M	28.91M	75.87M	67.10M	55.20M	62.50M
Gross Profit Ratio	3.12%	5.81%	5.43%	8.67%	5.07%	5.13%	6.54%	6.63%	5.79%	3.14%	2.07%	1.89%	1.41%	2.14%	2.58%	1.33%	1.88%	2.53%	2.31%	2.38%	2.71%	3.46%	3.56%
Research & Development	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	273.73M	263.11M	212.88M	192.53M	170.94M	171.00M	155.03M	149.67M	177.04M	153.96M	115.49M	101.46M	152.14M	113.84M	96.09M	73.85M	73.24M	65.19M	15.44M	53.04M	30.30M	27.50M	26.80M
Other Expenses	0.00	454.12M	364.29M	334.14M	353.81M	279.45M	309.05M	297.94M	303.81M	222.94M	204.93M	147.44M	4.80M	3.53M	2.99M	2.88M	2.25M	1.53M	390.00K	4.79M	18.80M	17.70M	0.00
Operating Expenses	266.33M	717.23M	577.17M	526.67M	524.75M	450.45M	464.08M	447.61M	480.85M	376.90M	320.42M	248.90M	156.94M	117.37M	99.08M	76.73M	75.49M	66.71M	15.83M	57.82M	49.10M	45.20M	26.80M
Cost & Expenses	16.25B	18.50B	13.11B	8.13B	12.94B	12.47B	8.80B	8.14B	10.20B	17.10B	19.50B	17.54B	14.78B	7.75B	5.77B	8.98B	6.71B	4.43B	1.24B	3.17B	2.46B	1.58B	1.72B
Interest Income	0.00	81.26M	80.09M	83.54M	89.86M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	85.63M	81.26M	80.09M	83.54M	89.86M	89.15M	86.23M	86.32M	73.33M	47.76M	43.54M	36.27M	31.21M	22.31M	15.19M	20.80M	17.41M	11.90M	2.69M	4.70M	2.00M	2.20M	3.00M
Depreciation & Amortization	110.09M	104.80M	102.24M	100.14M	108.19M	106.84M	105.65M	111.94M	13.50M	18.87M	19.22M	45.46M	30.36M	20.08M	2.99M	15.13M	9.61M	4.11M	953.00K	3.23M	0.00	-1.10M	26.07M
EBITDA	356.36M	565.08M	244.46M	285.24M	234.32M	304.01M	225.44M	-42.11M	114.72M	252.07M	161.27M	130.05M	85.71M	69.43M	53.74M	43.01M	51.49M	46.51M	14.03M	21.28M	18.00M	8.90M	35.70M
EBITDA Ratio	2.16%	2.06%	1.15%	2.47%	1.14%	1.66%	1.44%	1.31%	1.26%	1.07%	0.53%	0.74%	0.56%	0.89%	0.92%	0.65%	0.70%	1.12%	1.12%	0.67%	0.73%	0.56%	2.04%
Operating Income	243.77M	460.29M	142.22M	192.27M	139.21M	197.17M	119.78M	-152.25M	114.72M	165.71M	85.41M	84.59M	50.63M	49.35M	50.75M	43.07M	51.49M	46.51M	13.08M	18.05M	18.00M	10.00M	19.90M
Operating Income Ratio	1.48%	2.44%	1.07%	2.31%	1.06%	1.56%	1.34%	-1.85%	1.11%	0.96%	0.44%	0.48%	0.34%	0.63%	0.87%	0.48%	0.76%	1.04%	1.05%	0.57%	0.73%	0.63%	1.13%
Total Other Income/Expenses	-83.13M	-81.26M	-80.09M	-90.70M	-102.94M	-89.15M	-86.23M	-86.32M	-73.33M	-47.76M	-43.54M	-36.27M	-31.21M	-22.31M	-15.19M	-20.80M	-3.29M	-11.39M	6.01M	0.00	-2.00M	-4.00M	700.00K
Income Before Tax	160.64M	379.03M	62.13M	101.56M	36.27M	108.03M	33.55M	-238.57M	41.39M	117.94M	41.87M	48.32M	19.42M	27.04M	35.56M	22.21M	48.20M	35.13M	10.39M	0.00	16.00M	6.00M	20.60M
Income Before Tax Ratio	0.97%	2.01%	0.47%	1.22%	0.28%	0.85%	0.38%	-2.90%	0.40%	0.68%	0.21%	0.27%	0.13%	0.35%	0.61%	0.25%	0.71%	0.79%	0.83%	0.00%	0.65%	0.38%	1.17%
Income Tax Expense	8.14M	16.82M	1.34M	-119.00K	1.09M	5.62M	-23.56M	53.00K	-1.87M	963.00K	819.00K	1.58M	68.00K	0.00	1.43M	1.15M	1.19M	1.67M	986.00K	739.54K	0.00	5.10M	-10.27M
Net Income	152.51M	362.21M	60.80M	102.21M	35.87M	103.91M	58.75M	-199.41M	43.56M	114.71M	42.62M	46.74M	19.35M	27.04M	33.34M	21.06M	47.01M	33.46M	9.41M	17.31M	16.00M	6.00M	20.60M
Net Income Ratio	0.92%	1.92%	0.46%	1.23%	0.27%	0.82%	0.66%	-2.42%	0.42%	0.66%	0.22%	0.27%	0.13%	0.35%	0.57%	0.23%	0.70%	0.75%	0.75%	0.54%	0.65%	0.38%	1.17%
EPS	3.77	10.06	1.79	2.77	0.82	3.08	1.74	-5.95	1.12	3.97	1.43	1.73	0.88	1.61	2.56	1.57	1.38	2.46	1.60	3.07	2.84	1.06	3.65
EPS Diluted	3.76	10.02	1.77	2.74	0.81	3.06	1.74	-5.95	1.11	3.95	1.42	1.71	0.87	1.59	2.51	1.57	1.38	2.46	1.60	3.07	2.84	1.06	3.65
Weighted Avg Shares Out	33.97M	33.94M	33.94M	33.91M	33.81M	33.70M	33.59M	33.52M	32.18M	27.42M	27.33M	26.39M	21.28M	16.35M	13.02M	13.07M	12.44M	11.29M	5.64M	5.64M	5.64M	5.64M	5.64M
Weighted Avg Shares Out (Dil)	34.04M	34.04M	34.28M	34.31M	34.34M	33.97M	33.63M	33.53M	32.32M	27.50M	27.56M	26.57M	21.47M	16.60M	13.28M	13.07M	12.44M	11.29M	5.64M	5.64M	5.64M	5.64M	5.64M

Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says

July 30, 2024cnbc.com

An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial. Novo Nordisk sells liraglutide under the brand names Saxenda...

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

July 30, 2024globenewswire.com

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

July 26, 2024seekingalpha.com

Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032....

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

July 22, 2024prnewswire.com

Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and...

Hims & Hers Health: Expecting A Healthy Report

July 21, 2024seekingalpha.com

Hims & Hers Health has fallen below $20 after initial excitement over a compounded GLP-1 drug solution wanes. The health and wellness platform offers a compounded semaglutide drug at lower prices due to shortage of name-brand drugs. A short report...

Hims & Hers: The Thesis Goes Far Beyond GLP-1

July 18, 2024seekingalpha.com

Hims & Hers is dedicated to telehealth and provides healthcare services remotely. It has an asset-light business model that has had extraordinary growth. The company began its growth by attacking markets sometimes overlooked by traditional medicine, such as dermatology or...

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

July 17, 2024accesswire.com

DehydraTECH appears to work with a second GLP-1 drug - liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 Dosing in the final four study arms...

Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity

July 17, 2024businesswire.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule...

Dario Expands GLP-1 Solution Client Base with New Employer Contract

July 16, 2024prnewswire.com

Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets NEW YORK , July 16, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market,...